Products
Zinlirvimab Biosimilar Monoclonal Antibody (HIV-1 gp120 V3) for Research
Cat No.: GMP-Bios-INN-1477
Anti-HIV-1 gp120 V3 therapeutic antibody (Pre-made Zinlirvimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Zinlirvimab (development codes 10-1074/GS-2872) is a monoclonal antibody targeting HIV-1 gp120 envelope glycoprotein. It is developed by Gilead for HIV-1 infections, AIDS in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1477-1mg | 1mg | 3090 |
| GMP-Bios-INN-1477-10mg | 10mg | |
| GMP-Bios-INN-1477-100mg | 100mg | |
| GMP-Bios-INN-1477-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Zinlirvimab biosimilar, Whole mAb: Anti-HIV-1 gp120 V3 therapeutic antibody |
| INN Name | Zinlirvimab |
| Target | HIV-1 gp120 V3 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | 6orn:AB:FI:OP/6udk:AB:FI:OP/6udj:AR:KL:QB/6v8z:DE:PQ:JK/6ccb:DE:HL/6okp:KL/7ucf:HL/7ucg:HL:JK:QR/7ugn:MP:NQ:OR/7ugo:MP:NQ:OR/7ugp:MP:NQ:OR/7ugq:MP:NQ:OR/8czz:MN:OP:QR/8dok:MN:OP:QR/8g6u:MN:OP:QR/8ttw:MN:OP:QR/9bew:HL:JK:QR |
| 99% SI Structure | 5t3x:HL/5t3z:HL |
| 95-98% SI Structure | 4fq2:HL |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | Gilead |
| Conditions Approved | na |
| Conditions Active | HIV-1 infections;AIDS |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
